Application of fluorogold in tumor innervation tracking
By using fluorescent gold microinjection technology and NF-200 immunofluorescence staining in mouse breast cancer models, the problem of judging tumor innervation type and connection status was solved, providing a basis for selecting tumor nerve blocking therapy and peripheral and central nerves. Research reference for impact.
Patent Information
- Application Number
- CN202411068883.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art is difficult to accurately judge the innervation types of different types of tumors and their connection with the peripheral and central nerves of the body, which affects the effectiveness of tumor nerve therapy and clinical treatment choices.
The nerve source innervation of mouse breast cancer and its connection to the peripheral and central nerves was observed and depicted by using fluorescent gold microinjection technology in mouse breast cancer models.
The neural source of breast cancer in mice and its connection to the peripheral and central nervous system was successfully portrayed, providing a basis for drug selection for cancer nerve blocking therapy and helping to study the effects of tumors on the peripheral and central nervous system.
Smart Images

Figure CN119023635A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to the application of fluorescent gold in tumor nerve innervation tracking. Background Art
[0002] Nerves are an important component of the tumor microenvironment, and the degree of tumor innervation is positively correlated with poor prognosis. Blocking the communication between tumors and nerves may become a new tumor treatment approach similar to inhibiting angiogenesis in tumors. Although tumor denervation, including surgical resection or drug blockade, can inhibit tumor progression and improve prognosis, the effectiveness of tumor neurotherapy varies greatly among different types of tumors and even individuals. The types of nerves that innervate different types of tumors are different, which is the main factor affecting clinical benefits. Therefore, determining the type of innervation of different tumors and their connection with the body's original peripheral and central nervous systems is a key step in promoting the application of tumor neurotherapy. Tumor neoplastic nerves are different from the body's original nerves. They generally do not form larger nerve bundles, but are mostly dispersed in the form of tiny nerve fibers. This also leads to the inability of clinical pathological analysis through HE staining to accurately judge the degree of innervation of tumor tissues, and cannot help clinicians choose appropriate anticancer regimens.
[0003] Nerve tracing has been an important tool for defining central nervous system circuits. Fluorogold has been widely used in retrograde neuronal tracing studies. Fluorogold nerve tracing technology can enhance the study of tumor innervation by providing a method to identify and map neural sources that may directly and indirectly affect the tumor microenvironment. Summary of the invention
[0004] The purpose of the present invention is to provide an application of fluorescent gold in tumor nerve innervation tracking. By using a mouse breast cancer model, fluorescent gold is microinjected into the tumor, combined with immunofluorescence staining of the neuron-specific marker protein NF-200, the connection between the nerves innervating mouse breast cancer and the original peripheral nerves and central nerves of the body is observed.
[0005] The application specifically includes the following steps: Step 1, using mouse breast cancer cell line 4T1 and BALB / c mice, constructing a mouse orthotopic breast cancer model by injection into the mammary fat pad, and allowing the tumor to grow for 14 days; Step 2: On the 15th day after tumor inoculation, the retrograde neural tracer fluorescein was injected into the tumor by microinjection. Three days after the injection, samples were collected, including DRG and spinal cord, frozen sections were made, and fluorescein in the mouse DRG and spinal cord was observed under a fluorescence microscope.
[0006] The present invention successfully depicted the origin of the nerves that control mouse breast cancer and their connections with the peripheral and central nerves through fluorescent gold intratumoral microinjection. This will provide a basis for the selection of neurological drugs for cancer nerve blockade therapy and provide a reference for studying the impact of tumors on peripheral nerves and even central nerves. BRIEF DESCRIPTION OF THE DRAWINGS
[0007] Figure 1 These are the fluorescent images of DRG (A) and the posterior horn of the spinal cord (B) in Example 1. DETAILED DESCRIPTION
[0008] The preferred embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that the following examples are provided only for the purpose of illustration and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.
[0009] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0010] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources. Example 1
[0011] 1. Establishment of an orthotopic breast cancer transplant model in mice The experimental method is as follows: (1) Preparation of cell suspension: Breast cancer 4T1 cells were digested, centrifuged and counted to prepare a cell suspension with a number concentration of 1×10 6 / mL of cell suspension.
[0012] (2) Injection of cancer cells into the mammary fat pad of mice: SPF female BALB / c mice weighing 15-20 g were anesthetized using an isoflurane-containing gas anesthesia device and placed on an operating table where anesthesia could be maintained. The abdomen was shaved with a shaver and the skin was prepared. The surgical site was disinfected locally with alcohol cotton balls. 100 μL of cell suspension was drawn with a syringe and injected into the fourth fat pad of the mice. The mice were kept for 14 days after surgery to establish a tumor model.
[0013] 2. Local injection of fluorescent gold into the tumor The experimental method is as follows: The mice were anesthetized using an isoflurane-containing gas anesthesia device and placed on an operating table that could maintain anesthesia. The skin at the tumor site was exposed and disinfected with alcohol. 3 μL of fluorescent gold was drawn using a microsyringe and aimed at the center of the tumor. The injection was completed after the needle was inserted about 5 mm. The mice were kept for 3 days after the injection, and then painlessly killed to obtain the DRG and spinal cord corresponding to the tumor site.
[0014] 3. The mouse DRG and spinal cord were fixed, dehydrated, and then frozen and sectioned. Immunofluorescence staining (NF-200) was performed and Fluoro Gold was observed under a fluorescence microscope.
[0015] like Figure 1 As shown, by tumor microinjection of fluorescent gold combined with neuron-specific marker protein immunofluorescence staining, the newly generated axons in the tumor can be traced back to the local dorsal root ganglia and the corresponding segmental spinal cord, indicating that the nerve fibers in the tumor originate from the peripheral nerves and establish connections with the DRG and spinal cord.
Claims
1. Application of fluorescent gold in tumor innervation tracking.
2. The use according to claim 1, characterized in that: The following steps are involved: Step 1, using mouse breast cancer cell line 4T1 and BALB / c mice, constructing a mouse orthotopic breast cancer model by injection into the mammary fat pad, and allowing the tumor to grow for 14 days; Step 2: On the 15th day after tumor inoculation, the retrograde neural tracer fluorescein was injected into the tumor by microinjection. Three days after the injection, samples were collected, including DRG and spinal cord, frozen sections were made, and fluorescein in the mouse DRG and spinal cord was observed under a fluorescence microscope.
